Something else must be putting a spanner in the works - what do you think that might be?
In the high-stakes world of biotech drug development, failure is common. Over 90% of drugs in development never make it to market. But the real issue often isn't the science itself; it's the leadership. An A-class leadership team can turn even a mediocre asset into a winner, whereas a B-class team will likely fumble even the most promising discoveries.